Hepregen Corporation Announces Appointment of Dr. Michael Holsapple as Vice President of Toxicology Product Development
MEDFORD, Mass.--(BUSINESS WIRE)--Hepregen Corporation, developer of next generation HepatoPacTM and HepatoMuneTM products, announced today the appointment of Dr. Michael P. Holsapple as Vice President of Toxicology Product Development. This appointment of Dr. Holsapple, who will also retain his position at Battelle Memorial Institute (“Battelle”), was accomplished as a part of an investment and commercial development strategy co-elaborated by senior management at Hepregen and Battelle.
Following a successful 13-year academic career, Dr. Holsapple was leader of the Immunotoxicology and Respiratory Toxicology groups at Dow Chemical for eight years, after which, from 2002 to 2011, he served as the Executive Director of the Health and Environmental Sciences Institute (HESI), the global branch of the International Life Sciences Institute (ILSI) in Washington, DC. He joined Battelle in 2011 as a Senior Leader Research in systems toxicology. Dr. Holsapple received the Society of Toxicology (SOT) Achievement Award in 1992. In recognition of his contributions to immunotoxicology, he received the Vos Award: Career Achievement in Immunotoxicology in 2009. Dr. Holsapple has served on Council for the SOT, and on Council for the American College of Toxicology (ACT). He was elected a ‘fellow’ in the Academy of Toxicological Sciences (ATS) in 2006, and a member of the Board of Trustees of the ATS in 2013. He is also a past President of the SOT.
Dr. Holsapple stated, “Hepregen has become the leader in next generation in vitro micro-liver products. Joining the Company’s outstanding team of scientists and commercially experienced senior managers is without a doubt an exceptional opportunity to participate in development of products that can transform the pharmaceutical, cosmetics and chemical industries.”
“Mike’s incredibly extensive scientific and organizational background in the field of toxicology provides Hepregen with an unmatched resource,” stated Dr. Vincent Zurawski, Hepregen’s chief executive officer, adding, “He brings a wealth of knowledge and experience to our emerging global enterprise.”
About Hepregen Corporation
Hepregen Corporation is the undisputed leader in innovating unique and proprietary bioengineered micro-liver platforms for use in environmental testing, preventive care, and pharmaceutical, biotherapeutic and diagnostic product development. The Company’s micro-liver HepatoPacTM and HepatoMuneTM products support a potential paradigm shift in drug development. The utility of Hepregen’s human, rat, monkey and dog HepatoPacTM and HepatoMuneTM products has been validated in collaboration with investigators at several well-known pharmaceutical companies. Additionally, new applications for these products are being tested by Hepregen, its pharmaceutical company customers, and its academic and business partners. Hepregen was founded and capitalized by Battelle Venture Partners with technology licensed from the Massachusetts Institute of Technology. The technology was developed by Professor Sangeeta Bhatia, who is a world renowned expert and leader in liver bioengineering for life science and therapeutic applications. She currently chairs the Company’s scientific advisory board. For more information, visit http://www.hepregen.com.
Hepregen Corporation Katherine Sydney, 1-781-391-0205